At a glance
ClinicalIndex Comparison Record- ✓Healthy non-smokers: age 21-70 with normal spirometry and no history of respiratory/allergic disease.
- ✓Healthy smokers: age 21-70 with ≥10 pack-year smoking history and normal spirometry.
- ✓COPD subjects: age 40-75 with ≥20 pack-year smoking history.
- ✓COPD subjects: FEV1:FVC ratio <0.7 post-bronchodilator, post-bronchodilator FEV1 <85% predicted, and reversibility <15% of predicted FEV1 (all three required).
- ✕Pregnant women or breastfeeding mothers.
- ✕Unable to provide informed consent.
- ✕COPD subjects: any exacerbation, oral steroid, or antibiotic use within preceding 6 weeks.
- ✕Clinically significant findings on history or physical examination (other than COPD in COPD group).
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Leukocyte Migration and Differentiation in COPD Patients Compared to Healthy Smokers and Healthy Non-smoking Subjects.
In Brief
An observational study for COPD and 2 related conditions. Completed, enrolled 100 participants across 1 site.
Detailed Summary
The aim of this study is to investigate the mechanisms whereby leukocytes are recruited to the lung in chronic obstructive pulmonary disease (COPD) and cause tissue destruction. The hypothesis is that in COPD more leukocytes enter the lung and it is these cells that are responsible for the degradation of lung tissue. We, the researchers at Imperial College London, will isolate leukocytes from the blood of patients with COPD, healthy smokers and normal subjects and measure the movement of the leukocytes to chemoattractants. We will examine further, which cell surface receptors are responsible for this trafficking of cells. Furthermore, the differentiation of these cells in vitro will be compared with cells from healthy smokers and normal subjects. Specifically, the expression of enzymes that are responsible for tissue destruction and the cell surface receptors on these cells will be investigated. The objective is to identify the mechanisms whereby leukocytes from COPD patients behave differently to cells from healthy smokers and normal subjects with a view to identify novel targets for drug therapy.